%0 Journal Article
%T National Institute of Allergy and Infectious Disease (NIAID) Funding for Studies of Hospital-Associated Bacterial Pathogens: Are Funds Proportionate to Burden of Disease?
%A Seunghyug Kwon
%A Marin L Schweizer
%A Eli N Perencevich
%J Antimicrobial Resistance and Infection Control
%D 2012
%I BioMed Central
%R 10.1186/2047-2994-1-5
%X The NIH Research Portfolio Online Reporting Tools (RePORT) database was used to identify NIAID antimicrobial resistance research grants funded in 2007-2009 using the terms "antibiotic resistance," "antimicrobial resistance," and "hospital-associated infection."Funding for antimicrobial resistance grants has increased from 2007-2009. Antimicrobial resistance funding for bacterial pathogens has seen a smaller increase than non-bacterial pathogens. The total funding for all ESKCAPE pathogens was $ 22,005,943 in 2007, $ 30,810,153 in 2008 and $ 49,801,227 in 2009. S. aureus grants received $ 29,193,264 in FY2009, the highest funding amount of all the ESCKAPE pathogens. Based on 2009 funding data, approximately $1,565 of research money was spent per S. aureus related death and $750 of was spent per C. difficile related death.Although the funding for ESCKAPE pathogens has increased from 2007 to 2009, funding levels for antimicrobial resistant bacteria-related grants is still lower than funding for antimicrobial resistant non-bacterial pathogens. Efforts may be needed to improve research funding for resistant-bacterial pathogens, particularly as their clinical burden increases.The National Institutes of Health (NIH) has been successful over the past 60 years in funding research that has greatly advanced modern medicine. However, given limited resources, many have begun to question how these research funds are allocated to various diseases.[1-3] The NIH has listed five major criteria for the allocation of research funds: public health needs, the scientific quality of research, the probability of success, the maintenance of a diverse portfolio, and the maintenance of an adequate scientific infrastructure.[4] While the Institute of Medicine panel has embraced these criteria as an appropriate framework for funding, they also concluded that the NIH does not adequately describe how public health need is assessed, and recommended the use of burdens and costs of diseases in streng
%K Antibiotic resistance
%K NIH
%K Hospital-associated infection
%K research funding
%K disease burden
%U http://www.aricjournal.com/content/1/1/5